两性霉素B捕获的天然主要外膜蛋白加Resiquimod佐剂增强抗衣原体保护
本研究在小鼠鼻内攻击模型中评估以天然主要外膜蛋白(nMOMP)与两性霉素B(amphipol)及Resiquimod偶联的疫苗配方。结果显示,nMOMP/Resiq-A8-35联合Montanide和CpG-1826佐剂可诱导最强的保护性免疫应答,表现为抗体中和能力增强、T细胞增殖及IFN-γ、IL-6、IL-17产生增加、攻击后体重丢失减少和肺部衣原体回收减少。
要点
- nMOMP与Resiquimod偶联的两性霉素B复合物可增强保护性免疫。
- 加入Montanide和CpG-1826进一步改善Th1/Th2免疫应答。
- 保护效果依据抗体中和、T细胞增殖、体重丢失和肺部IFU回收评估。
核心结论
- nMOMP与Resiquimod偶联的两性霉素B复合物疫苗可增强保护性免疫应答,加入Montanide和CpG-1826后保护效果进一步提升。
研究设计与样本
- 小鼠鼻内攻击模型,比较nMOMP/A8-35、nMOMP/Resiq-A8-35及添加游离Resiquimod、Montanide ISA 720和CpG-1826的免疫效果,并以C. muridarum EB免疫为阳性对照、MEM缓冲液为阴性对照。
主要发现
- 所有实验组与阴性对照组相比均显示保护。
- Resiquimod单独诱导的体液和细胞免疫应答较弱,而Montanide和CpG-1826均显著增强这两种应答。
- 单独添加CpG-1826使免疫应答转向Th1偏倚。
- 三种佐剂联合偶联Resiquimod组诱导最强的保护,表现为抗体中和能力增强、T细胞增殖及IFN-γ、IL-6、IL-17产生增加、攻击后10天体重丢失减少和肺部IFU回收减少。
关键数值与推荐
- 保护效果评估参数包括:抗体中和C. muridarum的能力、体外T细胞增殖及IFN-γ、IL-6、IL-17产生、攻击后10天体重丢失、攻击后第10天肺部IFU回收数。
临床怎么用
- 该疫苗配方策略可能为衣原体疫苗开发提供候选方案,但尚需进一步临床前和临床研究验证。
局限性
- 研究仅在小鼠模型中进行,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A new vaccine formulated with the Chlamydia muridarum native major outer membrane protein (nMOMP) and amphipols was assessed in an intranasal (i.n.) challenge mouse model. nMOMP was trapped either in amphipol A8-35 (nMOMP/A8-35) or in A8-35 conjugated with Resiquimod (nMOMP/Resiq-A8-35), a TLR7/8 agonist added as adjuvant. The effects of free Resiquimod and/or additional adjuvants, Montanide ISA 720 (TLR independent) and CpG-1826 (TLR9 agonist), were also evaluated. Immunization with nMOMP/A8-35 alone administered i.n. was used as negative adjuvant-control group, whereas immunizations with C. muridarum elementary bodies (EBs) and MEM buffer, administered i.n., were used as positive and negative controls, respectively. Vaccinated mice were challenged i.n. with C. muridarum and changes in body weight, lungs weight and recovery of Chlamydia from the lungs were evaluated. All the experimental groups showed protection when compared with the negative control group. Resiquimod alone produced weak humoral and cellular immune responses, but both Montanide and CpG-1826 showed significant increases in both responses. The addition of CpG-1826 alone switched immune responses to be Th1-biased. The most robust protection was elicited in mice immunized with the three adjuvants and conjugated Resiquimod. Increased protection induced by the Resiquimod covalently linked to A8-35, in the presence of Montanide and CpG-1826 was established based on a set of parameters: (1) the ability of the antibodies to neutralize C. muridarum; (2) the increased proliferation of T-cells in vitro accompanied by higher production of IFN-γ, IL-6 and IL-17; (3) the decreased body weight loss over the 10 days after challenge; and (4) the number of IFUs recovered from the lungs at day 10 post challenge. In conclusion, a vaccine formulated with the C. muridarum nMOMP bound to amphipols conjugated with Resiquimod enhances protective immune responses that can be further improved by the addition of Montanide and CpG-1826.
引用
- Tifrea DF, Pal S, le Bon C, et al. Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant. Vaccine. 2020. PMID: 32386746. doi:10.1016/j.vaccine.2020.04.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。